Skip to main content

SS-31

Fixing the Body's Energy & Metabolic Machinery

Overview

Energy has a structure. We rarely talk about it that way, but the body produces energy through physical machinery—tightly organized membranes and protein complexes that convert fuel into usable power. When that machinery is young, energy is clean and predictable.

As it loosens with age, inflammation, stress, or illness, the same routines begin to feel heavier. Sleep becomes less restorative, recovery slows, and daily energy becomes more sensitive to disruptions such as dietary changes, infections, or prolonged exertion. Effort produces more strain and less usable output.

SS-31 is compelling because it targets this structural layer directly. It binds to cardiolipin—the lipid that holds the inner mitochondrial membrane together—and restores the tightness that efficient energy production depends on. When that structure is repaired, electron flow becomes cleaner, fewer byproducts accumulate, and the system generates more usable energy from the same signals.

This is not stimulation. It is structural repair. The difference matters. SS-31 does not push the system harder—it restores the hardware so normal physiology works the way it used to.

The Breakdown of Mitochondria

This structure loosens over time under the pressures of normal life. Each force is small on its own, but together they erode the structure that energy production depends on:

  • Chronic inflammation: Daily immune activity increases strain on the mitochondrial membrane and its lipid anchors.
  • Illness and infection: Fevers and strong immune responses push mitochondria to maximum output, leaving the membrane less organized.
  • Poor metabolic health: Glucose swings, insulin resistance, and impaired fat oxidation force mitochondria to work harder on a weakened scaffold.
  • Alcohol: Even moderate intake generates byproducts that repeatedly challenge membrane stability.
  • Environmental stressors: Heat, pollution, and toxins increase the energetic cost of maintaining homeostasis.
  • Sleep disruption: Deep sleep is when membrane repair programs run; shorter or fragmented sleep leaves restoration incomplete.
  • Prolonged psychological stress: Stress hormones increase demand while suppressing the nightly repair window.

These pressures accumulate slowly. The result is familiar: effort feels costlier, recovery takes longer, and energy becomes easier to disrupt—not because fuel is lacking, but because the membrane scaffolding has weakened as we age.

Mechanism of Action

SS-31 binds to cardiolipin on the inner mitochondrial membrane and restores the structural tension that keeps the respiratory machinery aligned. Once that structure is recovered:

  • Electron flow becomes cleaner: The complexes remain in position, reducing turbulence in the chain.
  • The membrane holds its charge more reliably: A tighter membrane sustains the gradient required for continuous energy production.
  • Mitochondria experience less internal strain: Cleaner flow produces fewer damaging intermediates, allowing each mitochondrion to function longer before requiring replacement.
  • Tissues meet demand with less effort: When the machinery moves electrons efficiently, work produces proportionate fatigue rather than exaggerated strain.

These are structural corrections, not forced output. SS-31 does not stimulate the system—it restores the architecture that makes clean energy possible.

System Behavior

When the membrane is restored, the system becomes more predictable under load. Energy no longer swings sharply with small stressors. Physical effort produces proportional fatigue instead of delayed crashes. Recovery windows shorten because tissues can power repair programs cleanly rather than working against internal inefficiency.

Daily variability narrows. A poor night’s sleep, a missed meal, or a mild illness still registers, but the impact is smaller because the underlying machinery remains stable. The system regains margin—more output from the same inputs, fewer penalties for routine disruptions.

Effort becomes smoother not because the system is stimulated, but because the machinery is no longer leaking energy as it works.

Who Benefits

People notice SS-31 when their energy has become harder to stabilize—slower recovery, disproportionate fatigue after mild exertion, or a sense that daily routines cost more than they should. These patterns reflect structural mitochondrial drift.

  • Aging adults
    Membrane tension declines with age, making energy less predictable and recovery slower. SS-31 is used intermittently—short repair phases spaced through the year—to restore alignment and maintain steadier daily output.

  • GLP-1 and tri-agonist users
    Rapid fat oxidation increases mitochondrial workload. SS-31 supports the hardware during high oxidative flux.

  • Low-energy phenotypes
    Chronic fatigue, post-exertional malaise, and energy fragility often stem from unstable mitochondrial structure. SS-31 is used when these symptoms intensify, then tapered once stability returns.

  • Post-viral or post-illness recovery
    Immune activation and inflammation stress mitochondrial membranes. SS-31 is used through the recovery window to re-establish clean energy production.

  • High physical demand individuals
    Athletes, shift workers, and people under sustained cognitive or physical load accumulate mitochondrial strain faster. SS-31 is used around heavy training blocks or intense work cycles.

  • Hormonal transition (peri-menopause, andropause)
    Inflammation, sleep disruption, and metabolic instability increase during transition phases. SS-31 helps stabilize energy by reinforcing membrane structure under increased strain.

Across these contexts, the principle is the same: SS-31 is used when life loads the mitochondrial membrane beyond its ability to maintain structure.

Dosing

SS-31 behaves as a structural repair signal rather than a continuous therapy. Typical practice uses:

  • Loading: 5–10 mg daily for 5–10 days
  • Maintenance: 5–10 mg, 2–3× per week
  • Timing: Morning or 60–90 minutes before training
  • Cycle: Intermittent use, aligned with stressors rather than fixed schedules

SS-31 works by attaching to the inner membrane of mitochondria and stabilizing the “scaffolding” that keeps the energy-producing machinery aligned.

Once those membrane sites are occupied, adding more SS-31 doesn’t increase the effect.

Because the benefit comes from membrane saturation—not how much SS-31 is in the bloodstream—it’s used in intermittent bursts rather than as a continuous therapy.

Tolerability is high; transient warmth, brief nausea may occur early and typically resolve quickly. Mild fatigue is expected in the initial portion of the loading phase if baseline mitochondrial damage is significant.

NAD⁺ & MOTS-c Synergies

NAD⁺ Conservation Through Structural Repair

SS-31 reduces the cellular “NAD⁺ burn rate” by fixing the structural problems that waste it. When the inner mitochondrial membrane is stable, electron flow stops leaking, oxidative byproducts drop, and the PARP-driven DNA-repair penalty shrinks. That lowers one of the biggest drains on the NAD⁺ pool.

It also quiets the inflammatory signals that normally drive CD38 expression—the enzyme that shreds NAD⁺ during immune activation.

Net effect: cells don’t just make energy more efficiently; they spend far less NAD⁺ doing it.

MOTS-c Synergy

Mitochondrial performance depends on three things: structure, signaling, and cofactor availability. SS-31 restores the structural layer so electrons move cleanly. MOTS-c switches on the adaptive program—more mitochondria, better substrate use, and higher metabolic resilience.

Together, the system gains both better engines (SS-31) and more engines (MOTS-c), producing cleaner, steadier energy under real-world load.

The Mitochondrial Stack

Known as Mitochondrial Integration & Transformation Triad (MITT), this stack combines SS-31 with NAD⁺ and MOTS-c to simultaneously repair the hardware, improve the adaptive software, and supply the cofactor reserve that mitochondrial performance depends on.

NAD⁺ supplies the redox currency mitochondria run on. MOTS-c expands oxidative capacity and improves fuel choice. SS-31 repairs the physical infrastructure that determines how efficiently that capacity can be used.

Stacked together, the three compounds address the constraints that determine energy stability: build quality, adaptive range, and cofactor supply. The result is a mitochondrial system that runs younger than its chronological age.

Clinical Research & Human Studies

Human trials have focused on diseases where mitochondrial structure is most impaired. In Barth syndrome, a genetic disorder defined by defective cardiolipin remodeling, SS-31 (elamipretide) showed improvements in functional capacity and cardiac performance over months to years of treatment. These findings contributed to its 2025 accelerated approval as Forzinity—the first mitochondria-targeted therapeutic authorized in the United States.

In primary mitochondrial myopathy, SS-31 did not meet the primary endpoint in the MMPOWER-3 trial but showed consistent directional benefits across secondary measures, including patient-reported fatigue and functional parameters. Studies in older adults demonstrated acute increases in skeletal-muscle ATP production following a single IV dose, confirming target engagement in aging tissue.

Ophthalmology programs explored SS-31 in dry AMD and LHON, reflecting the peptide's relevance to tissues with high energetic demand. Results were mixed overall but suggested benefit in specific subgroups. Expanded-access reports across rare mitochondrial diseases, including CPEO-plus, MPAN, and severe pediatric presentations, describe symptomatic improvement or stabilization when conventional options were limited.

Across studies, the mechanistic signal has been consistent: SS-31 reaches its mitochondrial target, stabilizes the membrane, reduces byproduct formation, and improves efficiency in tissues under energetic strain. Functional outcomes vary by indication, but the structural effects are reproducibly observed.

Discovery

SS-31 emerged from work on cardiolipin—the structural lipid that anchors the respiratory chain and preserves the tight curvature of the inner mitochondrial membrane. Researchers observed that when cardiolipin is damaged or loses its binding integrity, electron transfer becomes inefficient and mitochondrial output collapses long before the organelle itself fails. Restoring cardiolipin structure became a mechanistic target for conditions marked by fragile energy: cardiomyopathies, mitochondrial myopathies, and age-related decline.

The peptide was designed to localize directly to the inner membrane and stabilize cardiolipin without altering upstream signaling. Early work demonstrated that SS-31 could restore cristae structure, reduce electron leak, and improve coupling efficiency between oxygen consumption and ATP production. These findings guided its progression into human studies.

Regulatory Status

Elamipretide (SS-31) achieved FDA accelerated approval in 2025 under the trade name Forzinity for Barth syndrome, the first mitochondria-targeted therapeutic approved in the United States. A confirmatory post-marketing study is ongoing as part of the accelerated-approval framework. The compound also holds orphan-drug and rare pediatric disease designations.

For all non-Barth indications, elamipretide remains investigational. This reflects economic constraints around developing a specialized mitochondrial therapeutic across diverse chronic conditions, not a safety limitation. Access for other mitochondrial diseases occurs through expanded-access programs and investigator-led protocols.

References

Human Studies

  • Barth Syndrome – TAZPOWER Phase 2/3 + Extension (Genet Med, 2021–2024)
    Multi-year improvements in 6-minute walk distance and cardiac biomarkers; basis for accelerated approval.

  • Primary Mitochondrial Myopathy – MMPOWER-3 (Neurology, 2023)
    Primary endpoint not met; secondary outcomes showed directional benefit in fatigue and patient-reported function.

  • Older Adults – ATPmax Study (PLoS ONE, 2021)
    A single IV dose increased in vivo skeletal-muscle ATP production, confirming target engagement in aging muscle.

  • Dry AMD – ReCLAIM-2 (Ophthalmology Science, 2024)
    Mixed results overall with functional signal in predefined subgroups.

  • Failing Human Heart Tissue – JACC Basic Transl Sci (2019)
    Ex vivo human myocardium exposed to SS-31 showed improved mitochondrial respiration, supporting translational relevance.